Venture-capital backed Argen-X BV of Belgium has secured its first corporate partnership in a deal with Eli Lilly and Co to discover and develop therapeutic antibodies against targets supplied by the US company. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
